INDIAN PHARMACOPOEIA COMMISSION

National Coordination Centre- Pharmacovigilance Programme of India (PvPI)

MINISTRY OF HEALTH & FAMILY WELFARE, GOVERNMENT OF INDIA

SECTOR-23, RAJ NAGAR, GHAZIABAD- 201 002.

Tel No: 0120- 2783392, 2783400, 2783401 Fax: 0120-2783311

e-mail: pvpi@ipcindia.net, ipclab@vsnl.net, Web: www.ipc.gov.in

File No.-IPC/NCC-PvPI/NABH/2016-17/.01 **Date-21st Dec, 2016**

CIRCULAR

This is to inform all Government and Non Government/Corporate Hospitals that, The Indian Pharmacopoeia Commission (IPC), an autonomous institution of Ministry of Health and Family Welfare, Government of India has been entrusted with the responsibility relating to Pharmacovigilance Programme of India (PvPI) since April 2011. The Objective of PvPI is to improve patient safety and welfare of Indian population by monitoring drug safety and thereby reducing the risks associated with the use of medicines.

Pharmacovigilance is based on sound scientific principles and is an integral part of effective clinical practices. The discipline need to develop further to meet the demands of public health for which continuous monitoring of drugs is essentials. Such monitoring will help in assessing, monitoring and detecting adverse effects of drugs, their interactions etc. that can result in higher morbidity and mortality. The initiative will help to maximize benefits and minimize risks associated with drugs.

The Pharmacovigilance and Adverse Drug Reaction (ADR) reporting among healthcare professionals needs to be scaled up. It can be done by developing educational and promotional interventions like continuous medical education, awareness programme, workshops, conferences on pharmacovigilance, etc.

I would request to all Government and Non Government/Corporate Hospitals to support this Programme for the patient safety.

Again it is emphasized that reporting of adverse events shall not have any legal obligation on reporter, therefore your active participation in ADR reporting is need of the hour.

(Dr. G. N. Singh)
Secretary-cum-Scientific Director

Copy to-

1. Drug Controller General (India)
2. CEO, NABH-QCI
3. PS to Joint Secretary(R), MoHFW